Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrochlorothiazide

FDA-approved product (tablet, oral), marketed as Esidrix, Hydro-D, Hydrochlorothiazide and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrochlorothiazide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazides, plain; Thiazides, combinations with other drugs
FDA pharmacologic class
Thiazide Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrochlorothiazide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrochlorothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Role of Skin Sodium Accumulation in Chronic Kidney Disease

    NCT07020104 · start 2025-01-07

    Registered record
    Registry ID
    NCT07020104
    Conditions
    Chronic Kidney Diseases
    Interventions
    Hydrochlorothiazide; Spironolactone; Lercanidipine; High sodium dietary intake (>200mmol/l); Low sodium dietary intake (<50mmol/l); High water intake; Habitual water intake
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-01-07
    Completion
    2039-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases
    InterventionHydrochlorothiazide; Spironolactone; Lercanidipine; High sodium dietary intake (>200mmol/l) +3 more
    PhaseNot applicable
    Registry statusRecruiting

  • Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

    NCT05443932 · start 2024-03-04

    Registered record
    Registry ID
    NCT05443932
    Conditions
    Urolithiasis; Hyperoxaluria
    Interventions
    Dapagliflozin; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-03-04
    Completion
    2025-12-31
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrolithiasis; Hyperoxaluria
    InterventionDapagliflozin; Hydrochlorothiazide
    PhasePhase 4
    Registry statusUnknown

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Use of Diuretics in Maintenance Hemodialysis Patients Undergoing Bioimpedance-guided Fluid Management

    NCT04182854 · start 2019-10-28

    Registered record
    Registry ID
    NCT04182854
    Conditions
    Diuretic Abuse
    Interventions
    Furosemid hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-10-28
    Completion
    2021-07-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiuretic Abuse
    InterventionFurosemid hydrochlorothiazide
    PhaseNot applicable
    Registry statusUnknown

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

    NCT03640221 · start 2018-09-01

    Registered record
    Registry ID
    NCT03640221
    Conditions
    Hypertension; Diabetes Mellitus, Type 2
    Interventions
    Ertugliflozin; Hydrochlorothiazide 12.5mg; Microneurography; SKNA recordings; Static Handgrip; Post-handgrip forearm vascular occlusion; Testing of the Arterial Baroreflex Function
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-09-01
    Completion
    2020-08-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Diabetes Mellitus, Type 2
    InterventionErtugliflozin; Hydrochlorothiazide 12.5mg; Microneurography; SKNA recordings +3 more
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients

    NCT03946514 · start 2018-09-01

    Registered record
    Registry ID
    NCT03946514
    Conditions
    Hypertension
    Interventions
    losartan/hydrochlorothiazide; amlodipine/hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2024-08-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionlosartan/hydrochlorothiazide; amlodipine/hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

    NCT03387657 · start 2018-01-03

    Registered record
    Registry ID
    NCT03387657
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sotagliflozin (SAR439954); Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-03
    Completion
    2018-03-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSotagliflozin (SAR439954); Hydrochlorothiazide
    PhasePhase 1
    Registry statusCompleted

  • Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

    NCT02824718 · start 2017-06-06

    Registered record
    Registry ID
    NCT02824718
    Conditions
    Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment
    Interventions
    Teriparatide; Thiazide; Potassium sparing diuretic; Alfacalcidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-06-06
    Completion
    2020-05-28
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment
    InterventionTeriparatide; Thiazide; Potassium sparing diuretic; Alfacalcidol
    PhasePhase 2
    Registry statusCompleted

  • Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions

    NCT03031496 · start 2017-03-17

    Registered record
    Registry ID
    NCT03031496
    Conditions
    Hypertension
    Interventions
    GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets); Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-17
    Completion
    2017-04-10
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionGSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets); Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
    PhasePhase 1
    Registry statusCompleted

  • Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.

    NCT03006796 · start 2017-01-16

    Registered record
    Registry ID
    NCT03006796
    Conditions
    Arterial Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-01-16
    Completion
    2020-03-31
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Diuretic Comparison Project

    NCT02185417 · start 2016-06-15

    Registered record
    Registry ID
    NCT02185417
    Conditions
    Hypertension
    Interventions
    Hydrochlorothiazide (HCTZ); Chlorthalidone (CTD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-06-15
    Completion
    2022-12-29
    Enrolment
    20,723

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionHydrochlorothiazide (HCTZ); Chlorthalidone (CTD)
    PhasePhase 3
    Registry statusCompleted

  • RAS Peptide Profiles in Patients With Arterial Hypertension

    NCT02449811 · start 2015-04

    Registered record
    Registry ID
    NCT02449811
    Conditions
    Essential Hypertension
    Interventions
    Perindopril; Olmesartan; Amlodipine; Hydrochlorothiazide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-04
    Completion
    2018-11
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionPerindopril; Olmesartan; Amlodipine; Hydrochlorothiazide
    PhaseNot recorded
    Registry statusCompleted

  • A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323

    NCT02094924 · start 2014-04-17

    Registered record
    Registry ID
    NCT02094924
    Conditions
    Hypertension
    Interventions
    GSK587323; FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04-17
    Completion
    2014-05-23
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionGSK587323; FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
    PhasePhase 1
    Registry statusCompleted

  • Medication Adherence and "True" Resistance in Patients With Resistant Hypertension

    NCT02128386 · start 2014-02

    Registered record
    Registry ID
    NCT02128386
    Conditions
    Hypertensive Disease; Hypertension, Resistant to Conventional Therapy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-02
    Completion
    2016-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive Disease; Hypertension, Resistant to Conventional Therapy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown